查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1498717

癌症 Gamma Delta T 细胞治疗的全球市场：市场机会与临床试验见解 (2030)

Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030
出版日期: | 出版商: KuicK Research | 英文 240 Pages | 商品交期: 最快1-2个工作天内

价格

使用未来 T 细胞的免疫疗法长期以来一直在癌症治疗领域掀起风暴，但需要透过开发其他尖端疗法来扩大癌症免疫疗法的领域。然而，这仍然促使了其他 T 细胞受体的发现，例如 γδT 细胞和 αβT 细胞。随后，基于 γ δ T 细胞的免疫疗法被发现，基于 γ δ T 细胞的免疫疗法的开发可能成为治疗癌症以及包括病毒感染、自体免疫和发炎等其他疾病的创新疗法。治疗。

基于γ-δ T 细胞的免疫疗法的全球临床领先地位由30 种产品组成（截至2024 年6 月），其中一些产品处于临床前阶段，并需要该领域的持续研发和技术进步，其中大多数正在进行中。然而，治疗癌症和其他疾病的药物尚未进入商业市场。然而，一旦一种药物获得批准，其他基于 γδT 细胞的免疫疗法就会被推向市场，并有可能成为数百万美元的市场。

推动基于 γδT 细胞的免疫疗法市场成长的策略驱动力之一是临床前研究和临床试验的增加。在过去的十年中，全球基于 γδT 细胞的免疫疗法市场受到了一些新的、创新的和先进的竞争对手的发展的推动。例如，美国临床阶段生物技术公司Acepodia Biotech开发了两种竞争药物ACE1708和ACE2016，用于治疗表达PD-L1的实体肿瘤和表达EGFR的肿瘤。

本报告考察了全球癌症 γ δ T 细胞治疗市场，并提供了市场概况，包括其在癌症治疗中的作用、区域趋势、临床试验趋势以及进入市场的公司的竞争趋势。

目录

第1章 γ δ T 细胞疗法简介

  • 基于 T 细胞的免疫疗法的新兴作用
  • γδT 细胞疗法概述
  • γδT细胞疗法与常规疗法的比较

第2章 γ δ T 细胞在癌症中的作用

  • 癌症进展中的 γ δ T 细胞
  • γδT 细胞的抗肿瘤活性
  • 用于 γ δ T 细胞治疗的方法

第3章 全球γδT细胞治疗市场概述

  • 目前的市场情况
  • γδT细胞治疗市场的潜力

第4章 全球γδT细胞疗法临床试验概述

  • 相别
  • 依国家
  • 依公司
  • 依指示
  • 依优先权

第5章 依公司、国家、适应症和阶段分析全球 γ δ T 细胞疗法临床试验的见解

  • 研究
  • 临床前
  • 第一阶段
  • 一期/二期
  • 第二阶段

第6章 白血病的 Gamma Delta T 细胞治疗

第7章 肺癌的 Gamma Delta T 细胞治疗

第8章 乳癌中的 Gamma Delta T 细胞

第9章 大肠直肠癌中的Gamma Delta T细胞

第10章 胰臟癌中的 Gamma Delta T 细胞

第11章 淋巴瘤中的Gamma Delta T细胞

第12章 脑肿瘤的Gamma Delta T细胞疗法

第13章 头颈癌的γδT细胞疗法

第14章 Gamma Delta T 细胞治疗自体免疫疾病、发炎性疾病和微生物性疾病

  • 自体免疫疾病、发炎性疾病、微生物性疾病的研究与开发

第15章 γδT细胞疗法的联合治疗

第16章 γδT细胞疗法的发展平台

第17章 Gamma Delta T 细胞治疗市场动态

第18章 竞争格局

  • Acepodia
  • Adicet
  • Cytomed Therapeutics
  • Expression Therapeutics
  • Janssen Biotech
  • Gadeta
  • GammaDelta Therapeutics (Takeda)
  • IN8bio
  • Kiromic Biopharma
  • Lava Therapeutics
  • Regeneron Pharmaceuticals
  • TC Biopharm

Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030 Report Conclusions:

  • Number Of Gamma Delta T Cell Therapies In Trials: > 30 Therapies
  • US & China Dominating Clinical Trials Landscape: > 20 Therapies
  • Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase
  • Gamma Delta T Cell Therapy Future Market Opportunity By Different Cancers
  • Insight On Clinical Platforms for Evolving Gamma Delta T Cell Therapy: > 10 Platforms By Companies
  • Ongoing Clinical Research & Development Trends By Different Cancers
  • Insight On 12 Companies Developing Gamma Delta T Cell Therapies

After vicennium of futuristic T cells entrenched immunotherapy dominating the treatment landscape of cancer arena, there is a prerequisite to branch out cancer immunotherapy realm by developing other state-of-the-art therapies. But in spite of that, this led to discovery of other T cells receptors, such as gamma delta T cells, alpha-beta T cell and others. Consecutively, finding of gamma delta T cells based immunotherapy (also recognized as Yδ T cells), it was further pragmatic that developing gamma delta T cells based immunotherapies will aid to offer a innovatory treatment for cancer along with other disorders, including viral infections, autoimmune and inflammation.

With respect to KuicK Research statistics, the global clinical conduit of gamma delta T cells based immunotherapy comprises of 30 drugs (as of June 2024), several of which are in preclinical stage as well as majority of research and development along with technological advancement in in this sector is ongoing in the US and China region. Albeit, no drug has penetrated into the commercial market to treat cancer or other ailments; however, as soon as one drug will get approved will aid to launch other gamma delta T cells based immunotherapy into market and clenches potential to become a multimillionaire market in imminent.

One of the strategic prime movers that bestow to bourgeon the growth of gamma delta T cells based immunotherapy market is the rise in preclinical and clinical studies. Over the preceding decennium, the sphere of global gamma delta T cells based immunotherapy market has witnessed the development of several novel, innovative as well as advanced competitors. For instance, a clinical-stage biotechnology company in US, Acepodia Biotech has developed 2 contenders, ACE1708 as well as ACE2016 to treat solid tumor expressing PD-L1 accompanied with EGFR expressing tumors.

Coupled with this, the presences of various stakeholders in conjugation with investors from giant pharma companies accompanied with biotech companies, such as Bristol Myers Squibb, TC Biopharm, PersonGen BioTherapeutics, In8bio, Kiromic BioPharma, Immatics, Legend Biotech, Innate Pharma, Ever Supreme Bio Technology, Editas Medicine, CytoMed Therapeutics, Acepodia Biotech and other have bestowed to transform the treatment paradigm by developing up-to-the-minute gamma delta T cells based immunotherapy worldwide. Amid all these companies, PersonGen BioTherapeutics is the frontrunner in this segment as the company is developing 5 allogeneic UCAR- Yδ1 T cell therapy for the treatment of autoimmune, T cell malignancies and other solid tumors. The presences of giant pharmaceuticals aid to conduct multitudinous clinical trials in gamma delta T cells based immunotherapy space.

Just as importantly, an inclining market trend towards developing avant-garde global gamma delta T cells based immunotherapy, such as developing gamma-delta gene editing based immunotherapy, is gaining spotlight amid healthcare professionals. For instance, a biotech company based in Germany, Immatics has collaborated with Bristol Myers Squibb and Editas Medicine in order To syndicate gamma-delta T cell based adoptive cell therapies in addition to gene editing for the treatment of cancer.

Until now, no gamma delta T cells based immunotherapies has been approved in global market; nevertheless, it can be anticipated that a handful of gamma delta T cells therapies will be launched into the market in approaching 5 to 7 years due to the fact that many gamma delta T cells based immunotherapies have received FDA designations which aid to accelerate the approval process. For instance, ADI-001 has gained utmost breakthrough as it has received FDA fast track designation for the potential treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (NHL), in 2022, and relapsed/refractory class III or class IV lupus nephritis in June 2024. Overall, aforementioned illustrates clearly forecasts that the future of gamma delta T cells based immunotherapies will be propitious.

Table of Contents

1. Introduction To Gamma Delta T Cell Therapy

  • 1.1 Emerging Role of T Cell Based Immunotherapies
  • 1.2 Overview of Gamma Delta T Cell Therapy
  • 1.3 Gamma Delta T Cell Therapy v/s Conventional Therapies

2. Role of Gamma Delta T Cells in Cancer

  • 2.1 Gamma Delta T Cells in Cancer Progression
  • 2.2 Anti Tumor Activity of Gamma Delta T Cells
  • 2.3 Adopted Approaches for Gamma Delta T Cell Therapy

3. Global Gamma Delta T Cell Therapy Market Overview

  • 3.1 Current Market Scenario
  • 3.2 Market Potential of Gamma Delta T Cell Therapy Market

4. Global Gamma Delta T Cell Therapy Clinical Trials Overview

  • 4.1 By Phase
  • 4.2 By Country
  • 4.3 By Company
  • 4.4 By Indication
  • 4.5 By Priority Status

5. Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase

  • 5.1 Research
  • 5.2 Preclinical
  • 5.3 Phase I
  • 5.4 Phase I/II
  • 5.5 Phase II

6. Gamma Delta T Cell Therapy in Leukemia

  • 6.1 Ongoing Clinical Research & Development Trends
  • 6.2 Future Market Opportunity of Gamma Delta T Cells in Leukemia

7. Gamma Delta T Cell Therapy in Lung Cancer

  • 7.1 Ongoing Clinical Research & Development Trends
  • 7.2 Future Market Opportunity of Gamma Delta T Cell Therapy in Lung Cancer

8. Gamma Delta T Cells in Breast Cancer

  • 8.1 Ongoing Clinical Research & Development Trends
  • 8.2 Future Market Opportunity of Gamma Delta T Cell Therapy in Breast Cancer

9. Gamma Delta T Cells in Colorectal Cancer

  • 9.1 Ongoing Clinical Research & Development Trends
  • 9.2 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer

10. Gamma Delta T Cells in Pancreatic Cancer

  • 10.1 Ongoing Clinical Research & Development Trends
  • 10.2 Future Market Potential of Gamma Delta Therapy in Pancreatic Cancer

11. Gamma Delta T Cells in Lymphoma

  • 11.1 Ongoing Clinical Research & Development Trends
  • 11.2 Future Outlook in Lymphoma

12. Gamma Delta T Cell Therapy in Brain Tumors

  • 12.1 Research & Development in Brain Tumors
  • 12.2 Future Outlook in Brain Tumors

13. Gamma Delta T Cell Therapy in Head & Neck Cancer

  • 13.1 Research & Development in Head & Neck Cancer
  • 13.2 Future Outlook in Head & Neck Cancer

14. Gamma Delta T Cell Therapy in Autoimmune, Inflammatory & Microbial Ailments

  • 14.1 Research & Development in Autoimmune, Inflammatory & Microbial Ailments

15. Combination Methodologies for Gamma Delta T Cell Therapy

16. Platforms for Evolving Gamma Delta T Cell Therapy

17. Gamma Delta T Cell Therapy Market Dynamics

  • 17.1 Gamma Delta T Cell Therapy Market: Favorable Parameters
  • 17.2 Gamma Delta T Cell Therapy Market: Challenges

18. Competitive Landscape

  • 18.1 Acepodia
  • 18.2 Adicet
  • 18.3 Cytomed Therapeutics
  • 18.4 Expression Therapeutics
  • 18.5 Janssen Biotech
  • 18.6 Gadeta
  • 18.7 GammaDelta Therapeutics (Takeda)
  • 18.8 IN8bio
  • 18.9 Kiromic Biopharma
  • 18.10 Lava Therapeutics
  • 18.11 Regeneron Pharmaceuticals
  • 18.12 TC Biopharm

List of Tables

  • Table 3-1: Candidates with Regulatory Designations
  • Table 6-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2024-2030
  • Table 6-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2024-2030
  • Table 6-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2024-2030
  • Table 6-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2024-2030
  • Table 6-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2024-2030
  • Table 7-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2024-2030
  • Table 7-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2024-2030
  • Table 7-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2024-2030
  • Table 7-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2024-2030
  • Table 7-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2024-2030
  • Table 8-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2024-2030
  • Table 8-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2024-2030
  • Table 8-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2024-2030
  • Table 8-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2024-2030
  • Table 8-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2024-2030
  • Table 9-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2024-2030
  • Table 9-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2024-2030
  • Table 9-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2024-2030
  • Table 9-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2024-2030
  • Table 9-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2024-2030
  • Table 10-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2024-2030
  • Table 10-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2024-2030
  • Table 10-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2024-2030
  • Table 10-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2024-2030
  • Table 10-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2024-2030
  • Table 11-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Lymphoma , 2024-2030
  • Table 11-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Lymphoma , 2024-2030
  • Table 11-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Lymphoma, 2024-2030
  • Table 11-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Lymphoma , 2024-2030
  • Table 11-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Lymphoma , 2024-2030
  • Table 12-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Brain Tumors, 2024-2030
  • Table 12-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Brain Tumors, 2024-2030
  • Table 12-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Brain Tumors, 2024-2030
  • Table 12-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Brain Tumors , 2024-2030
  • Table 12-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Brain Tumors , 2024-2030
  • Table 13-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Head & Neck Cancers, 2024-2030
  • Table 13-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Head & Neck Cancers, 2024-2030
  • Table 13-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Head & Neck Cancer, 2024-2030
  • Table 13-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Head & Neck Cancers, 2024-2030
  • Table 13-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Head & Neck Cancer, 2024-2030
  • Table 15-1: Ongoing Preclinical & Clinical Trials for Combination of Gamma Delta T Cell Therapy

List of Figures

  • Figure 1-1: History of T cell Based Immunotherapy
  • Figure 1-2: Gamma Delta T cell Therapy
  • Figure 1-3: Stimulants of Gamma Delta T Cells
  • Figure 1-4: Limitation of CAR T Cell Therapy
  • Figure 1-5: Limitations of TIL
  • Figure 1-6: Limitations of Monoclonal Antibodies
  • Figure 1-7: Drawbacks of Chemotherapeutic Drugs
  • Figure 2-1: Pro-Tumor Role of Gamma Delta T Cells
  • Figure 2-2: Antigen Presentation Functions of Gamma Delta T-Cells
  • Figure 2-3: Anti-Tumor Activity of Gamma Delta T-Cells
  • Figure 2-4: Gamma Delta T Cell Bispecific Antibodies - Mechanism of Action
  • Figure 2-5: Functional Advantages of Gamma-Delta T Cells for CAR T Cancer Therapy
  • Figure 2-6: CAR Gamma-Delta T Cells - Mechanism of Action
  • Figure 3-1: Global - Cell Therapy Market (US$ Billion), 2024 - 2030
  • Figure 3-2: Global - Gamma Delta T Cell Therapy Market Opportunity by 1% of Total Cell Therapy Market (US$ Billion), 2024-2030
  • Figure 3-3: Global - Gamma Delta T Cell Therapy Market Opportunity by 2% of Total Cell Therapy Market (US$ Billion), 2024-2030
  • Figure 3-4: Global - Gamma Delta T Cell Therapy Market Opportunity by 3% of Total Cell Therapy Market (US$ Billion), 2024-2030
  • Figure 3-5: Global - Gamma Delta T Cell Therapy Market Opportunity by 4% of Total Cell Therapy Market (US$ Billion), 2024-2030
  • Figure 3-6: Global - Gamma Delta T Cell Therapy Market Opportunity by 5% of Total Cell Therapy Market (US$ Billion), 2024-2030
  • Figure 3-7: Global - Gamma Delta T Cell Therapy Market Opportunity by 6% of Total Cell Therapy Market (US$ Billion), 2024-2030
  • Figure 3-8: Global - Gamma Delta T Cell Therapy Market Opportunity by 7% of Total Cell Therapy Market (US$ Billion), 2024-2030
  • Figure 3-9: Global - Gamma Delta T Cell Therapy Market Opportunity by 8% of Total Cell Therapy Market (US$ Billion), 2024-2030
  • Figure 3-10: Global - Gamma Delta T Cell Therapy Market Opportunity by 9% of Total Cell Therapy Market (US$ Billion), 2024-2030
  • Figure 3-11: Global - Gamma Delta T Cell Therapy Market Opportunity by 10% of Total Cell Therapy Market (US$ Billion), 2024-2030
  • Figure 4-1: Global - Gamma Delta T Cell Therapy Clinical Trials By Phase (Numbers), 2024 - 2030
  • Figure 4-2: Global - Gamma Delta T Cell Therapy Clinical Trials By Country (Numbers), 2024 - 2030
  • Figure 4-3: Global - Gamma Delta T Cell Therapy Clinical Trials By Company (Numbers), 2024 - 2030
  • Figure 4-4: Global - Gamma Delta T Cell Therapy Clinical Trials By Indication (Numbers), 2024
  • Figure 4-5: Global - Gamma Delta T Cell Therapy Clinical Trials By Priority Status (Numbers), 2024
  • Figure 6-1: Benefits of Gamma Delta T Cells in Leukemia
  • Figure 6-2: CD33CART Phase 1/2 (NCT03971799) Study - Initiation & Completion Year
  • Figure 6-3: CD33CART Phase 2 (NCT03971799) Study - Initiation & Completion Year
  • Figure 6-4: INB-100 Phase 1 (NCT03533816) Study - Initiation & Completion Year
  • Figure 6-5: Mechanism of Action of VGamma-9/CD123 Bispecific Antibody
  • Figure 6-6: Global - Estimated Leukemia Cases, 2024-2030
  • Figure 6-7: US - Estimated Leukemia Cases, 2024-2030
  • Figure 6-8: Europe - Estimated Leukemia Cases, 2024-2030
  • Figure 6-9: China - Estimated Leukemia Cases, 2024-2030
  • Figure 6-10: Japan - Estimated Leukemia Cases, 2024-2030
  • Figure 7-1: Role of Gamma Delta T Cells in Lung Cancer
  • Figure 7-2: KB-GDT-01 Phase 1 (NCT06069570) Study - Initiation & Completion Year
  • Figure 7-3: Global - Estimated Lung Cancer Cases, 2024-2030
  • Figure 7-4: US - Estimated Lung Cancer Cases, 2024-2030
  • Figure 7-5: Europe - Estimated Lung Cancer Cases, 2024-2030
  • Figure 7-6: China - Estimated Lung Cancer Cases, 2024-2030
  • Figure 7-7: Japan - Estimated Lung Cancer Cases, 2024-2030
  • Figure 8-1: Global - Estimated Breast Cancer Cases, 2024-2030
  • Figure 8-2: US - Estimated Breast Cancer Cases, 2024-2030
  • Figure 8-3: Europe - Estimated Breast Cancer Cases, 2024-2030
  • Figure 8-4: China - Estimated Breast Cancer Cases, 2024-2030
  • Figure 8-5: Japan - Estimated Breast Cancer Cases, 2024-2030
  • Figure 9-1: Role of Gamma Delta T Cells in Colorectal Cancer
  • Figure 9-2: Mechanism Underlying B7-H3 Regulating Gamma-Delta T Cells Killing Colon Cancer Cells
  • Figure 9-3: PF-08046052 Phase I (NCT05983133) Study - Initiation & Completion Year
  • Figure 9-4: Global - Estimated Colorectal Cancer Cases, 2024-2030
  • Figure 9-5: US - Estimated Colorectal Cancer Cases, 2024-2030
  • Figure 9-6: Europe - Estimated Colorectal Cancer Cases, 2024-2030
  • Figure 9-7: China - Estimated Colorectal Cancer Cases, 2024-2030
  • Figure 9-8: Japan - Estimated Colorectal Cancer Cases, 2024-2030
  • Figure 10-1: Auspicious Outcomes Gamma Delta T Cell Therapy
  • Figure 10-2: Role of Gamma Delta T Cells in Pancreatic Cancer Progression
  • Figure 10-3: Global - Estimated Pancreatic Cancer Cases, 2024-2030
  • Figure 10-4: US - Estimated Pancreatic Cancer Cases, 2024-2030
  • Figure 10-5: Europe - Estimated Pancreatic Cancer Cases, 2024-2030
  • Figure 10-6: China - Estimated Pancreatic Cancer Cases, 2024-2030
  • Figure 10-7: Japan - Estimated Pancreatic Cancer Cases, 2024-2030
  • Figure 11-1: ACE1831 Phase I (NCT05653271) Study - Initiation & Completion Year
  • Figure 11-2: ADI-001 Phase I (NCT04735471) Study - Initiation & Completion Year
  • Figure 11-3: Global - Estimated Lymphoma Cases, 2024-2030
  • Figure 11-4: US - Estimated Lymphoma Cases, 2024-2030
  • Figure 11-5: Europe - Estimated Lymphoma Cases, 2024-2030
  • Figure 11-6: China - Estimated Lymphoma Cases, 2024-2030
  • Figure 11-7: Japan - Estimated Lymphoma Cases, 2024-2030
  • Figure 12-1: DeltEx With Temozolomide (TMZ) Phase 1/2 (NCT05664243) Study - Initiation & Completion Year
  • Figure 12-2: IN8bio - Autologous (INB-400) & Allogeneic (INB-410) Candidates
  • Figure 12-3: Gamma-Delta T Cells Phase 1 (NCT04165941) Study - Initiation & Completion Year
  • Figure 12-4: Aflac-NBL-2002 Phase 1 (NCT05400603) Study - Initiation & Completion Year
  • Figure 12-5: Global - Estimated Brain Cancer Cases, 2024-2030
  • Figure 12-6: US - Estimated Brain Tumor Cases, 2024-2030
  • Figure 12-7: Europe - Estimated Brain Tumor Cases, 2024-2030
  • Figure 12-8: China - Estimated Brain Tumor Cases, 2024-2030
  • Figure 12-9: Japan - Estimated Brain Tumor Cases, 2024-2030
  • Figure 13-1: Acepodia Biotech Clinical Pipeline Insight
  • Figure 13-2: Pfizer & Lava Therapeutics Collaboration
  • Figure 13-3L: SGN-EGFRd2 Phase 1 (NCT05983133) Study - Initiation & Completion Year
  • Figure 13-4: Global - Estimated Head & Neck Cancer Cases, 2024-2030
  • Figure 13-5: US - Estimated Head & Neck Cancer Cases, 2024-2030
  • Figure 13-6: Europe - Estimated Head & Neck Cancer Cases, 2024-2030
  • Figure 13-7: China - Estimated Head & Neck Cancer Cases, 2024-2030
  • Figure 13-8: Japan - Estimated Head & Neck Cancer Cases, 2024-2030
  • Figure 14-1: ADI-001 Phase 1 (NCT06375993) Study - Initiation & Completion Year
  • Figure 14-2: Adicet Bio ADI-001 Fast Track Designation
  • Figure 14-3: ImCheck Therapeutics - Clinical Candidates Indications & Mode of Action Insights
  • Figure 14-4: ICT21 - Mechanism of Action
  • Figure 15-1: Gamma Delta T Cell Therapy Combinations
  • Figure 16-1: IN8bio - DeltEx DRI Auto
  • Figure 16-2: Diamond AI - Prediction Engine
  • Figure 16-3: Diamond AI - Immune Surveillance
  • Figure 16-4: Acepodia - Antibody-Cell Conjugation
  • Figure 16-5: Lava Therapeutics - Gammabody Platform
  • Figure 16-6: Adicet Bio - Gamma Delta Cell Platform
  • Figure 16-7: ADI-001 - Gamma Delta Cell Therapy
  • Figure 16-8: Century Therapeutics - Allo-Evasion
  • Figure 16-9: ViGenCell - ViRanger Platform
  • Figure 16-10: Legend Biotech - CAR-Gamma-Delta T Platform
  • Figure 16-11: Immatics - ACTallo-R Manufacturing Process
  • Figure 17-1: Global - Cancer Incidences & Mortality Rates (Billion), 2020 & 2040
  • Figure 17-2: Gamma Delta T Cells Favorable Market Parameters
  • Figure 17-3: Stages of Drug Development